Zusammenfassung
Die idiopathische Lungenfibrose ist eine chronisch progrediente fibrosierende interstitielle Pneumonie unbekannter Ursache, die primär beim älteren Erwachsenen auftritt und sich radiologisch sowie histologisch durch das Vorliegen eines UIP-Musters („Usual Interstitial Pneumonia“) auszeichnet. Die Prognose ist ungünstig, interindividuell ist der Verlauf jedoch sehr variabel. Die zentrale Säule der Diagnostik ist die hochauflösende Computertomografie, eine Histologiegewinnung ist nur selten erforderlich. Die Diagnosestellung sollte in einer interdisziplinären Fallevaluation erfolgen. Therapeutisch stellt die Lungentransplantation die einzige kurative Option dar. Mit den antifibrotisch wirksamen Substanzen Pirfenidon oder Nintedanib kann eine Progressionsverzögerung erreicht werden. Supportive Ansätze sollten früh in die Behandlung integriert werden.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Akira M, Hamada H, Sakatani M, Kobayashi C, Nishioka M, Yamamoto S (1997) CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. AJR Am J Roentgenol 168:79–83
Allaix ME, Fisichella PM, Noth I et al (2014) Idiopathic pulmonary fibrosis and gastroesophageal reflux. Implications for treatment. J Gastrointest Surg 18:100–104. (discussion 4–5)
Behr J, Günther A, Bonella F et al (2018) German guideline for idiopathic pulmonary fibrosis – update on pharmacological therapies 2017. Pneumologie 72:155–168
Behr J, Günther A, Bonella F et al (2020) S2K-Leitlinie zur Diagnostik der idiopathischen Lungenfibrose. Pneumologie 74:263–293
Bettencourt PE, Del Bono EA, Spiegelman D, Hertzmark E, Murphy RL Jr (1994) Clinical utility of chest auscultation in common pulmonary diseases. Am J Respir Crit Care Med 150:1291–1297
du Bois RM, Weycker D, Albera C et al (2011a) Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 184:1382–1389
du Bois RM, Weycker D, Albera C et al (2011b) Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184:459–466
du Bois RM, Weycker D, Albera C et al (2011c) Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 183:1231–1237
Borensztajn K, Crestani B, Kolb M (2013) Idiopathic pulmonary fibrosis: from epithelial injury to biomarkers – insights from the bench side. Respiration 86:441–452
Carloni A, Poletti V, Fermo L, Bellomo N, Chilosi M (2013) Heterogeneous distribution of mechanical stress in human lung: a mathematical approach to evaluate abnormal remodeling in IPF. J Theor Biol 332:136–140
Collard HR, Anstrom KJ, Schwarz MI, Zisman DA (2007) Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 131:897–899
Collard HR, Ryerson CJ, Corte TJ et al (2016) Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med 194:265–275
Corte TJ, Wort SJ, Talbot S et al (2012) Elevated nocturnal desaturation index predicts mortality in interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 29:41–50
Cottin V, Nunes H, Brillet PY et al (2005) Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 26:586–593
Culver DA, Behr J, Belperio JA et al (2019) Patient registries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 200:160–167
Daniels CE, Yi ES, Ryu JH (2008) Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis. Eur Respir J 32:170–174
Dowman LM, McDonald CF, Hill CJ et al (2017) The evidence of benefits of exercise training in interstitial lung disease: a randomized controlled trial. Thorax 72:610–619
Hagmeyer L, Theegarten D, Treml M et al (2016) Validation of transbronchial cryobiopsy in interstitial lung disease – interim analysis of a prospective trial and critical review of the literature. Sarcoidosis Vasc Diffuse Lung Dis 33(1):2–9
Hagmeyer L, Theegarten D, Wohlschläger J et al (2019) Transbronchial cryobiopsy in fibrosing interstitial lung disease: modifications of the procedure lead to risk reduction. Thorax 74:711–714
Hetzel J, Maldonado F, Ravaglia C et al (2018) Transbronchial Cryobiopsies for the Diagnosis of Diffuse Parenchymal Lung Diseases: Expert Statement from the Cryobiopsy Working Group on Safety and Utility and a Call for Standardization of the Procedure. Respiration 95:188–200
Hoeper MM, Andreas S, Bastian A et al (2011) Pulmonary hypertension due to chronic lung disease: updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 154(1):45–53
Hopkins RB, Burke N, Fell C et al (2016) Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada. Eur Respir J 48:187–195
Huppmann P, Sczepanski B, Boensch M et al (2013) Effects of inpatient pulmonary rehabilitation in patients with interstitial lung disease. Eur Respir J 42:444–453
Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G (2014) Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 370:2093–2101
Jankowich MD, Rounds S (2010) Combined pulmonary fibrosis and emphysema alters physiology but has similar mortality to pulmonary fibrosis without emphysema. Lung 188:365–373
Kato E, Takayanagi N, Takaku Y et al (2018) Incidence and predictive factors of lung cancer in patients with idiopathic pulmonary fibrosis. ERJ Open Res 4:00111–02016
Khor YH, Ng Y, Barnes H et al (2020) Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review. Eur Respir Rev 29:190158
Kim DS (2013) Acute exacerbations in patients with idiopathic pulmonary fibrosis. Respir Res 14:86
Kim WY, Mok Y, Kim GW et al (2015) Association between idiopathic pulmonary fibrosis and coronary artery disease: a case-control study and cohort analysis. Sarcoidosis Vasc Diffuse Lung Dis 31:289–296
Kimura M, Taniguchi H, Kondoh Y et al (2013) Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis. Respiration 85:456–463
King TE Jr, Bradford WZ, Castro-Bernardini S et al (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370:2083–2092
Kitaguchi Y, Fujimoto K, Hanaoka M, Kawakami S, Honda T, Kubo K (2010) Clinical characteristics of combined pulmonary fibrosis and emphysema. Respirology 15:265–271
Kolb M, Raghu G, Wells AU et al (2018) Nintedanib plus Sildenafil in patients with idiopathic pulmonary fibrosis. N Engl J Med 379:1722–1731
Kolilekas L, Manali E, Vlami KA et al (2013) Sleep oxygen desaturation predicts survival in idiopathic pulmonary fibrosis. J Clin Sleep Med 9:593–601
Kreuter M, Ehlers-Tenenbaum S, Schaaf M et al (2015) Treatment and outcome of lung cancer in idiopathic interstitial pneumonias. Sarcoidosis Vasc Diffuse Lung Dis 31:266–274
Kreuter M, Bendstrup E, Russell AM et al (2017) Palliative care in interstitial lung disease: living well. Lancet Respir Med 5:968–980
Kreuter M, Ochmann U, Koschel D et al (2018) DGP interstitial lung disease patient questionnaire. Pneumologie 72:446–457
Kreuter M, Polke M, Walsh SLF et al (2020) Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonization. Eur Respir J 55:1901760
Lancaster LH, Mason WR, Parnell JA et al (2009) Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest 136:772–778
Le Jeune I, Gribbin J, West J, Smith C, Cullinan P, Hubbard R (2007) The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med 101:2534–2540
Lee JS, Collard HR, Anstrom KJ et al (2013) Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med 1:369–376
Ley B, Ryerson CJ, Vittinghoff E et al (2012) A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 156:684–691
Lynch DA, Sverzellati N, Travis WD et al (2018) Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med 6:138–153
Magnussen H, Kirsten AM, Kohler D et al (2008) Leitlinien zur Langzeit-Sauerstofftherapie. Pneumologie 62:748–756. (Deutsche Gesellschaft Fur Pneumologie und Beatmungsmedizin e. V.)
Maldonado F, Danoff SK, Wells AU et al (2020) Transbronchial cryobiopsy for the diagnosis of interstitial lung diseases: CHEST guideline and expert panel report. Chest 157:1030–1042
Mallick S (2008) Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensive care unit. Respir Med 102:1355–1359
Martinez FJ, Safrin S, Weycker D et al (2005) The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 142:963–967
Mejia M, Carrillo G, Rojas-Serrano J et al (2009) Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 136:10–15
Mermigkis C, Stagaki E, Tryfon S et al (2010) How common is sleep-disordered breathing in patients with idiopathic pulmonary fibrosis? Sleep Breath 14:387–390
Mermigkis C, Bouloukaki I, Antoniou KM et al (2013) CPAP therapy in patients with idiopathic pulmonary fibrosis and obstructive sleep apnea: does it offer a better quality of life and sleep? Sleep Breath 17:1137–1143
Moor CC, Mostard RLM, Grutters JC et al (2020) Home monitoring in patients with idiopathic pulmonary fibrosis. A rabdomized controlled trial. Am J Respir Crit Care Med 202:393–401
Nathan SD, Basavaraj A, Reichner C et al (2010) Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. Respir Med 104:1035–1041
Nathan SD, Behr J, Collard HR et al (2019) Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomized, placebo-controlled phase 2 b study. Lancet Respir Med 7:780–790
Noble PW, Albera C, Bradford WZ et al (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377:1760–1769
Orens JB, Estenne M, Arcasoy S et al (2006) International guidelines for the selection of lung transplant candidates: 2006 update – a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 25:745–755
Ozawa Y, Suda T, Naito T et al (2009) Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology 14:723–728
Panos RJ, Mortenson RL, Niccoli SA, King TE Jr (1990) Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 88:396–404
Park J, Kim DS, Shim TS et al (2001) Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J 17:1216–1219
Park JH, Kim DK, Kim DS et al (2007) Mortality and risk factors for surgical lung biopsy in patients with idiopathic interstitial pneumonia. Eur J Cardiothorac Surg 31:1115–1119
Perez-Bogerd S, Wuyts W, Barbier V et al (2018) Short and long-term effects of pulmonary rehabilitation in interstitial lung diseases: a randomized controlled trial. Respir Res 19:182
Raghu G, Freudenberger TD, Yang S et al (2006) High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 27:136–142
Raghu G, Rochwerg B, Zhang Y et al (2015) An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 192:e3–e19
Raghu G, Remy-Jardin M, Myers JL et al (2018) Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 198(5):e44–e68
Richeldi L, Costabel U, Selman M et al (2011) Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365:1079–1087
Russel AM, Adamali H, Molyneaux PL et al (2016) Daily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 194:989–997
Ryerson CJ, Arean PA, Berkeley J et al (2012) Depression is a common and chronic comorbidity in patients with interstitial lung disease. Respirology 17:525–532
Ryerson CJ, Hartman T, Elicker BM et al (2013) Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest 144:234–240
Shimbori C, Gauldie J, Kolb M (2013) Extracellular matrix microenvironment contributes actively to pulmonary fibrosis. Curr Opin Pulm Med 19:446–452
Smith JS, Gorbett D, Mueller J, Perez R, Daniels CJ (2013) Pulmonary hypertension and idiopathic pulmonary fibrosis: a dastardly duo. Am J Med Sci 346:221–225
Smits JM, Nossent GD, de Vries E et al (2011) Evaluation of the lung allocation score in highly urgent and urgent lung transplant candidates in Eurotransplant. J Heart Lung Transplant 30:22–28
Song JW, Hong SB, Lim CM, Koh Y, Kim DS (2011) Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 37:356–363
Sugino K, Ishida F, Kikuchi N et al (2014) Comparison of clinical characteristics and prognostic factors of combined pulmonary fibrosis and emphysema versus idiopathic pulmonary fibrosis alone. Respirology 19:239–245
Troy LK, Grainge C, Corte TJ et al (2020) Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study. Lancet Respir Med 8:171–181
Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B (2014) Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 349:209–220
Yanagihara T, Sato S, Upagupta C et al (2019) What have we learned from basic science studies on idiopathic pulmonary fibrosis? Eur Respir Rev 28:190029
Yang IV, Coldren CD, Leach SM et al (2013) Expression of cilium-associated genes defines novel molecular subtypes of idiopathic pulmonary fibrosis. Thorax 68:1114–1121
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Hagmeyer, L., Kahn, N., Kirsten, A.M., Kolb, M. (2022). Idiopathische Lungenfibrose. In: Kreuter, M., Costabel, U., Herth, F.J., Kirsten, D. (eds) Seltene Lungenerkrankungen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-63651-0_11
Download citation
DOI: https://doi.org/10.1007/978-3-662-63651-0_11
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-63650-3
Online ISBN: 978-3-662-63651-0
eBook Packages: Medicine (German Language)